Details of the Drug Combination

General Information of Drug Combination (ID: DC3OTNN)

Drug Combination Name
Picoplatin PMID28870136-Compound-43
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 PMID28870136-Compound-43   DMWGV8N
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCC-2998
Zero Interaction Potency (ZIP) Score: 1.77
Bliss Independence Score: 6.94
Loewe Additivity Score: 2.21
LHighest Single Agent (HSA) Score: 1.65

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Small-cell lung cancer 2C25.Y Phase 3 [2]
PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Glioblastoma DCK23YY SNB-75 Investigative [4]
Plasma cell myeloma DCCY238 RPMI-8226 Investigative [4]
Invasive ductal carcinoma DCQZXRE HS 578T Investigative [5]
Invasive ductal carcinoma DC5RRUJ BT-549 Investigative [5]
Adenocarcinoma DCF3H6N HT29 Investigative [1]
Amelanotic melanoma DCZKQ6D M14 Investigative [1]
Cutaneous melanoma DCKLUM4 SK-MEL-5 Investigative [1]
Cutaneous melanoma DC6NKK8 SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCTZYIH OVCAR-5 Investigative [1]
High grade ovarian serous adenocarcinoma DC6D82M NCI\\/ADR-RES Investigative [1]
Malignant melanoma DCUBEL0 LOX IMVI Investigative [1]
Non-small cell lung carcinoma DCSTD5I HOP-92 Investigative [1]
Pleural epithelioid mesothelioma DCAQ091 NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.